ALNY vs ANAB · P/E 76, rev $1.29B vs rev $234.6M
Alnylam Pharmaceuticals Inc (ALNY) versus AnaptysBio Inc (ANAB) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
AnaptysBio Inc (ANAB) is a biotechnology company listed on NASDAQ.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported ANAB revenue for 2025-12-31 was $234.6M. Net income was -$13.2M. ANAB currently screens at market cap $1.62B.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. ANAB currently screens at market cap $1.62B.
Not investment advice. Open the ALNY and ANAB stock pages for the full models.
Not investment advice.